Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

METHOTRIMEPRAZINE

All products: general benefit

Methoprazine · DIN 02238404 · 5mg · tablet

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Methoprazine · DIN 02238404 Manufacturer: A A Pharma Inc.; listing date 1999-04-15 Health Canada: Marketed since 2013-06-27 · brand METHOPRAZINE · ATC N05AA02 LEVOMEPROMAZINE · form Tablet · route Oral · ingredients METHOTRIMEPRAZINE (METHOTRIMEPRAZINE MALEATE) 5 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Methoprazine: Formulary list price $0.1043/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1043 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61821 · Verify on the e-Formulary ↗ (DIN 02238404)

Source record
DIN 02238404: Methoprazine Raw flags: sec3=Y Item: 282400019; group id 524; item number 1418; lccId None; manufacturer id AAP Source form: Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.1043; ministry $0.1043 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02238404 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61821
Interchangeable products
Nozinan · DIN 01927655 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (28:24 Sedatives and Hypnotics) and how they are covered

Matched class: 28:24 Sedatives and Hypnotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: NITRAZEPAM, PHENOBARBITAL, TEMAZEPAM Some products covered without a code (check the product listing): BUSPIRONE HYDROCHLORIDE, FLURAZEPAM, TRIAZOLAM 28:24 Sedatives and Hypnotics

BUSPIRONE HYDROCHLORIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 10mg · Tab

FLURAZEPAM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 15mg, 30mg · Cap

NITRAZEPAM

· 2 products · General benefit · strengths: 5mg, 10mg · Tab

PHENOBARBITAL

· 5 products · General benefit · strengths: 5mg/mL, 15mg, 30mg, 60mg, 100mg · Oral Elixir, Tab

TEMAZEPAM

· 2 products · General benefit · strengths: 15mg, 30mg · Cap

TRIAZOLAM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.125mg, 0.25mg · Tab

LORAZEPAM

· 9 products · Listed, not a benefit (1), Limited Use, codes 481 (2), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 4mg/mL, 0.5mg, 1mg, 2mg · Inj Sol (with preservative), SL Tab

MIDAZOLAM

· 3 products · Listed, not a benefit (1), Limited Use, codes 495, 496 (2) · strengths: 5mg/mL · Inj Sol (with Preservative)

ESZOPICLONE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg, 2mg, 3mg · Tab

ZOLPIDEM TARTRATE

· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg · SL Tab

ZOPICLONE

· 40 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 3.75mg, 5mg, 7.5mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:24
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:12 Anticonvulsants, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS NOZINAN (methotrimeprazine hydrochloride injection) is indicated for:  Psychotic disturbances: acute and chronic schizophrenias, senile psychoses, manic-depressive syndromes.  Analgesic: In pain due to cancer, zona, trigeminal neuralgia, neurocostal neuralgia, in phantom limb pains, muscular discomforts and as post-operative analgesic adjunct.  Antiemetic: For the treatment of nausea and vomiting of central origin.  Sedative: For the management of insomnia. 1.1 Pediatrics Pediatrics (<1 year of age): Contraindicated See 2 CONTRAINDICATIONS. Pediatrics (1 – 18 years of age): 4.2 4.2 Recommended Dose and Dosage Adjustment 1.2 Geriatrics Geriatrics (>65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness (see 7 WARNINGS AND PRECAUTIONS, 4.2 4.2 Recommended Dose and Dosage Adjustment NOZINAN is not indicated for the treatment of patients with dementia. See 3 SERIOUS WARNINGS AND PRECAUTIONS BOX. https://pdf.hres.ca/dpd_pm/00073362.PDF PM date: NOV 15, 2023 Source product: NOZINAN; DIN 01927698; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.